SCHEDULE: Saba Capital Boosts BlackRock Tech Trust Stake to 6.81%
Beneficial Ownership Disclosure (Amendment)
Saba Capital Management, L.P. and its affiliates have increased their beneficial ownership in BlackRock Science & Technology Term Trust to 6.81%, holding 4,682,590 common shares.
Summary
- Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein (Reporting Persons) collectively beneficially own 4,682,590 common shares of BlackRock Science & Technology Term Trust.
- This represents 6.81% of the issuer's common shares outstanding, calculated based on 68,744,150 shares as of June 30, 2025, as disclosed in the company's N-CSRS filed September 4, 2025.
- Approximately $80,499,717 was paid to acquire the common shares reported.
- Funds for the purchases were derived from investor subscription proceeds, capital appreciation, and margin account borrowings.
- The filing is Amendment No. 9 to a Schedule 13D, updating previous disclosures regarding beneficial ownership.
- Transactions within the past 60 days prior to January 14, 2026, included multiple purchases and some sales, with one pro-rata distribution in-kind for no consideration on November 28, 2025, involving 22,700 shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive from the perspective of Saba Capital increasing its stake, which could be seen as a vote of confidence and a precursor to potential value-enhancing actions. However, the filing is purely factual and does not contain explicit positive or negative statements about the issuer's performance.
Positives
- Saba Capital, a prominent investment manager known for activist strategies, has increased its significant stake, potentially signaling confidence in BlackRock Science & Technology Term Trust's underlying value.
- The total investment of approximately $80.5 million demonstrates a substantial commitment to the issuer.
Risks
- The use of margin account borrowings for share purchases introduces leverage risk, as positions held in margin accounts are pledged as collateral security for debit balances.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from the issuer or the reporting persons regarding the future performance of BlackRock Science & Technology Term Trust or Saba Capital's investment strategy beyond the disclosure of their current ownership.
Industry Context
This filing indicates a significant and increasing stake by Saba Capital, a known activist investor, in a closed-end fund like BlackRock Science & Technology Term Trust. Such large positions often precede or accompany efforts to influence fund management, governance, or distribution policies, particularly concerning discounts to Net Asset Value (NAV) common in closed-end funds. This aligns with a broader trend of activist funds targeting closed-end funds to unlock shareholder value.
Stakeholder Impact
- Shareholders: Increased institutional ownership by Saba Capital could potentially lead to future activist engagement, which might influence share price or corporate actions aimed at enhancing shareholder value.
- Management: Saba Capital's significant stake could prompt management to consider shareholder value initiatives more closely.
Key Dates
| Date | Description |
|---|---|
| 2015-11-16 | Date of power of attorney for Michael D'Angelo, incorporated by reference to Exhibit 2 of Schedule 13G filed on December 28, 2015. |
| 2015-12-28 | Date Schedule 13G was filed by Reporting Persons, containing the power of attorney. |
| 2025-06-30 | Date as of which 68,744,150 common shares were outstanding, as disclosed in the company's N-CSRS. |
| 2025-09-04 | Date the company's N-CSRS was filed, disclosing shares outstanding as of June 30, 2025. |
| 2025-11-19 | First reported transaction date (Buy 64,868 shares at $21.28). |
| 2025-11-20 | Buy 138,917 shares at $21.21. |
| 2025-11-21 | Buy 4,025 shares at $21.11. |
| 2025-11-24 | Sell 1,100 shares at $21.63. |
| 2025-11-25 | Sell 100 shares at $21.44. |
| 2025-11-28 | Buy 18,761 shares at $22.02 and Sell 22,700 shares at $0 (pro-rata distribution in-kind). |
| 2025-12-01 | Buy 9,210 shares at $22.23. |
| 2025-12-03 | Buy 81,646 shares at $22.26. |
| 2025-12-04 | Buy 45,490 shares at $22.51. |
| 2025-12-05 | Buy 38,850 shares at $22.74. |
| 2025-12-08 | Buy 25,834 shares at $22.83. |
| 2025-12-09 | Buy 25,268 shares at $22.89. |
| 2025-12-10 | Buy 40,540 shares at $22.97. |
| 2025-12-16 | Buy 15,458 shares at $22.31. |
| 2025-12-18 | Sell 10,482 shares at $22.62. |
| 2025-12-24 | Sell 1,790 shares at $22.89. |
| 2026-01-09 | Buy 15,188 shares at $22.82. |
| 2026-01-12 | Buy 22,208 shares at $22.82. |
| 2026-01-13 | Buy 44,573 shares at $22.78. |
| 2026-01-14 | Date of event requiring filing (Buy 43,130 shares at $22.64). |
| 2026-01-15 | Signature date for Saba Capital Management, L.P., Boaz R. Weinstein, and Saba Capital Management GP, LLC. |
Recommendation
holdThe filing indicates a significant and increasing stake by Saba Capital, a known activist investor, in BlackRock Science & Technology Term Trust. While this could signal potential future efforts to unlock shareholder value, the filing itself is a factual disclosure of ownership and does not provide new information on the issuer's financial performance or strategic direction. Investors should hold to observe any subsequent actions or communications from Saba Capital regarding their intentions for this investment.
Keywords
Saba Capital Management, BlackRock Science & Technology Term Trust, Schedule 13D/A, Beneficial Ownership, Investment Fund, Closed-End Fund, Technology Trust, Shareholder Activism, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.